VICL Key Stats
- Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma May 17
- Vical's CEO Presents at Bank of America Merrill Lynch 2013 Health Care Conferenc... May 14
- Short Interest In Vical Moves 21.2% Higher May 10
- VICAL INC Files SEC form 10-Q, Quarterly Report May 10
- Vical's CEO Discusses Q1 2013 Results - Earnings Call Transcript Seeking Alpha May 9
- Vical Earnings: Here’s Why Investors are Happy Now May 9
- Q1 2013 Vical Inc. Earnings Release - Before Market Open May 9
- Vical, Inc. (VICL) Reports In-Line Q1 Loss of 11c/Share Street Insider May 9
- Vical Reports First Quarter 2013 Financial Results and Progress in Key Developme... May 9
- VICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Fin... May 8
VICL Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Vical is up 26.41% over the last year vs S&P 500 Total Return up 31.68%, AEterna Zentaris down 23.08%, and Galena Biopharma up 63.09%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for VICL
Pro Report PDF for VICL
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download VICL Pro Report PDF
Pro Strategies Featuring VICL
Did Vical make it into our Pro Portfolio Strategies?